α 1 -antitrypsin deficiency is characterised by the misfolding and intracellular polymerisation of mutant α 1 -antitrypsin within the endoplasmic reticulum of hepatocytes. The retention of mutant protein causes hepatic damage and cirrhosis whilst the lack of an important circulating protease inhibitor predisposes the individuals with severe α 1 -antitrypsin deficiency to early onset emphysema. Our work over the past 25 years has led to new paradigms for the liver and lung disease associated with α 1 -antitrypsin deficiency. We review here the molecular pathology of the cirrhosis and emphysema associated with α 1 -antitrypsin deficiency and show how an understanding of this condition provided the paradigm for a wider group of disorders that we have termed the serpinopathies.
Introduction
We have described a group of protein conformational diseases that we have termed the serpinopathies [1] . They are characterised by the misfolding and intracellular polymerisation of members of the serine protease inhibitor or serpin superfamily. The best characterised of the serpinopathies is α 1antitrypsin deficiency [2] . This is one of the most common genetic disorders with the severe Z deficiency allele (Glu342Lys) being present in 1:25 of the North European Caucasian population of whom 1:2000 are homozygotes.
The Z mutation causes the retention of protein within hepatocytes in association with neonatal hepatitis, cirrhosis and hepatocellular carcinoma [3] [4] [5] . There is no specific treatment for the liver disease associated with α 1antitrypsin deficiency which accounts for 3.5% and 1.1% of paediatric and adult liver transplants in the UK respectively.
The lack of α 1 -antitrypsin, an important protease inhibitor, predisposes the Z homozygote to early onset panlobular basal emphysema [6] . α 1 -antitrypsin deficiency is the only known genetic cause of emphysema and is found in 1-2% of all individuals with chronic obstructive pulmonary disease (COPD); COPD will be the third commonest cause of death worldwide by 2020. The only treatment directly targeting the underlying pathobiology of the lung disease is α 1 -antitrypsin augmentation therapy which costs approximately $100,000/patient/year. Alpha 1 -antitrypsin deficiency accounts for 3.2% of adult lung transplants and 10% of all lung transplants for emphysema in the UK. Our work over the past 25 years has led to a new paradigm for α 1antitrypsin deficiency. Here we review the molecular basis of α 1 -antitrypsin deficiency and provide an update of the therapeutic strategies that are being developed.
Polymerisation: the central feature of α α α α 1 -antitrypsin deficiency
Alpha 1 -antitrypsin is the archetypal member of the serpin superfamily. The wild-type M protein is a 394 residue, 52kDa glycoprotein that is synthesised by hepatocytes, but is also produced by lung and gut epithelial cells, neutrophils and alveolar macrophages. Alpha 1 -antitrypsin is the major circulating antiprotease but its key function is regulation of the proteolytic effects of neutrophil elastase within the lung. We showed that the severe Z deficiency mutant of α 1 -antitrypsin is retained within the endoplasmic reticulum (ER) of hepatocytes as ordered polymers that become sequestered in Periodic Acid Schiff-positive, diastase-resistant inclusions [2, 7] . We have used biophysical and crystallographic techniques to dissect the pathway of α 1antitrypsin polymerisation [8] [9] [10] [11] [12] . Our work suggests that the Z mutation perturbs its local environment (breach region, Fig. 1A ) to favour population of an unstable intermediate that we termed M* [8] in which β-sheet A opens [2, 8] and the upper part of helix F unwinds [9, 13, 14] . The patent β-sheet A can then accept insertion of the reactive site loop motif. Sequential insertion of the loop of one α 1 -antitrypsin molecule into β-sheet A of a neighbour to form first a loop-sheet dimer, and then longer species linking more molecules, is the simplest model to explain the formation of elongated polymers [2, 8, 15] ( Fig. 1B(i) ). Indeed, polymerisation is blocked by peptides that mimic the reactive loop sequence and so compete for binding to the insertion site in βsheet A [2, 16] . We subsequently showed that the same process explains the profound plasma deficiency and hepatic inclusions of 3 other mutants of α 1antitrypsin: Siiyama (Ser53Phe) [17] , Mmalton (∆Phe52) [18] and King's (His334Asp) [7] . Polymerisation also underlies the deficiency of the mild S (Glu264Val), I (Arg39Cys), Queen's (Lys154Asn) and Baghdad (Ala336Pro) alleles of α 1 -antitrypsin [12, 14, 19, 20] but the rate of polymer formation is much slower in keeping with the absence of liver disease and only mild plasma deficiency. In many cases the reduction in the thermal stability of the native fold of α 1 -antitrypsin caused by mutations directly correlates with the polymerogenic tendency [11] . This implies that the mutants' conformational behaviour is qualitatively similar to that of wild-type α 1 -antitrypsin, but that destabilised states become accessible at lower temperatures. However in some cases, disease mutations appear to cause polymerisation more by altering the balance of conformational behaviour (kinetic destabilisation) between native and intermediate states to favour population of the latter [21] .
Importantly one such exception is the Z variant, that appears to cause a relatively mild thermal destabilisation but is highly polymerogenic [11, 12, 16] .
Understanding the polymerogenic behaviour of the most clinically-significant variant is important as it has relevance for the readouts that may be used in screening for therapeutic agents [16, 22] . Conversely, understanding the behaviour of rarer or milder variants in addition opens the way to precision medicine approaches, analogous to recent advances in cystic fibrosis [23, 24] .
Controversies on the structure of the pathological polymer
Our original description of polymers of Z α 1 -antitrypsin envisaged a linkage between the reactive centre loop and β-sheet A [2] ( Fig. 1B(i) ). Clinically, Z α 1 -antitrypsin inclusions within hepatocytes are increased by pyrexia and we assumed that polymers generated in vitro by heating purified Z α 1 -antitrypsin would be identical to those formed in vivo. We further assumed that polymers generated in vitro would be identical whether they were formed by heating purified Z α 1 -antitrypsin or incubation with denaturants (urea or guanidine) [8] .
However we now know the latter assumption was incorrect, and the former assumption is also a matter of debate [22] . An alternative linkage was suggested by the crystal structures of a dimer of antithrombin in which the molecules were linked by a β-hairpin of the reactive centre loop and strand 5A
[25] ( Fig. 1B (ii) ). The biophysical characteristics of polymers of α 1 -antitrypsin formed by refolding from guanidine gave support to the β-hairpin linkage [26] .
The cause of the disparate findings became clear with our development of the 2C1 monoclonal antibody that recognises polymers from the livers of individuals with α 1 -antitrypsin deficiency [7] . This antibody binds polymers formed by heating monomeric α 1 -antitrypsin, but not those formed by refolding from guanidine and urea [15] . Our NMR studies followed the polymerisation of Queen's (Lys154Asn) α 1 -antitrypsin under physiological conditions or in urea. Intermediate (M*) formation under physiological conditions was associated with highly native-like behaviour with changes in a few key motifs [14] . Global changes were observed in urea consistent with more widespread unfolding, in keeping with data from hydrogen-deuterium exchange [27] .
Consequently different polymeric linkages can be accessed by different denaturing conditions. The application of heat to monomeric α 1 -antitrypsin recapitulated the 2C1 neo-epitope of polymers associated with disease [15] .
This neo-epitope is also observed in self-terminating trimers of Z α 1antitrypsin artificially constrained by disulphide bonds and purified from the cytosol of a yeast expression system [28] . This species was crystallised and the structure determined to 3.9 Å resolution. The structure revealed yet another stable linkage mechanism, this time via complementary intermolecular insertion of the C-terminal triple-strand motif ( Fig. 1B (iii) ). This mechanism again requires a substantially unfolded intermediate state, 
Intracellular processing of α α α α 1 -antitrypsin polymers
Approximately 70% of Z α 1 -antitrypsin is degraded within hepatocytes by ER associated degradation (ERAD) [30] . Fifteen percent folds effectively and is secreted, while the remainder self-associates to form polymers. These are in part degraded by autophagy, but a proportion persist in intractable inclusions [30, 31] . Misfolded proteins within the ER lumen usually trigger adaptive measures termed the unfolded protein response (UPR). Indeed, terminally misfolded truncated variants of α 1 -antitrypsin (e.g., α 1 -antitrypsin Null-HongKong and Saar) constitutively activate the UPR [32, 33] . Surprisingly, the accumulation of Z α 1 -antitrypsin polymers within the ER is not associated with UPR activation in cell lines that recapitulate hepatocyte phenotypes or in transgenic mice, possibly because polymers are structurally ordered ( Fig. 3 ).
Instead Z α 1 -antitrypsin expression activates NFκB by a calcium-mediated pathway that is independent of the UPR [32] [33] [34] [35] . We have termed this the 'ordered protein response' [35] and others have shown that it results in the release of IL-6 and IL-8 [34] . These cytokines are well-recognised mediators of both acute and chronic inflammatory responses and so may play pathogenic roles in both the liver and lung disease associated with α 1antitrypsin deficiency. Moreover, cells expressing Z α 1 -antitrypsin display a more marked UPR when stressed with a 'second hit' [33, 34] . We have proposed that this results from α 1 -antitrypsin polymers increasing the viscosity within the ER thereby reducing the mobility of chaperones and hence their ability to neutralise the effect of a second insult [33] .
Alpha 1 -antitrypsin polymers, inflammation and emphysema
The study of the rare null mutations of α 1 -antitrypsin provides compelling evidence that the lack of circulating α 1 -antitrypsin plays a central role in the development of emphysema [36] . Consistent with this, α 1 -antitrypsin variants that fold more successfully and are less polymerogenic than the Z variant have higher circulating levels of α 1 -antitrypsin and appear to be associated with far lower risks of lung disease. Indeed such variants are typically described in association with lung disease in compound heterozygous states together with one Z allele (e.g. SZ individuals [37, 38] ). The recognition that polymers were present within hepatocytes raised the question that they may also be present within the lung. Polymers are detectable in bronchoalveolar lavage from Z α 1 -antitrypsin homozygotes [39] . They have even been found after a Z α 1 -antitrypsin individual had undergone a liver transplant i.e. the subject received a M α 1 -antitrypsin liver [40] . This elegant clinical experiment demonstrated that pulmonary polymers may arise from local production.
However we have been unable to detect polymers in our studies assessing primary bronchial epithelial cells [41] . Polymers of α 1 -antitrypsin form within the lung as a result of local inflammation and exposure to cigarette smoke [39, 40, 42, 43] . They are pro-inflammatory for human neutrophils in vitro [40, 44] and in murine lungs in vivo [42] . Moreover cigarette smoke induces both intrapulmonary polymer formation and neutrophil influx in transgenic mice that express Z, but not M α 1 -antitrypsin [43] . Polymers have also been identified in the skin of an individual with α 1 -antitrypsin deficiency and panniculitis and in a renal biopsy of an individual with α 1 -antitrypsin deficiency and vasculitis. We have recently shown that circulating polymers of α 1 -antitrypsin are present in all individuals with ZZ α 1 -antitrypsin deficiency (mean 36.3+/-SD33.3µg/mL; n=517) and that the level is associated with COPD (OR 3.6, 95% CI 1.4-9.1) [45] . These observations provide a new paradigm for the pathogenesis of the emphysema associated with α 1 -antitrypsin deficiency -a combination of loss of anti-protease function combined with pro-inflammatory intrapulmonary polymers [44] . However it is still unknown whether the pro-inflammatory properties of polymers play an important role in the pathogenesis of the emphysema associated with α 1 -antitrypsin deficiency or whether the majority of the pathology is driven by the deficiency in the antiproteinase screen ( Fig.   3 ). Also, the balance of polymers derived from plasma Z α 1 -antitrypsin and from local production within the lung is unresolved.
Polymers and the serpinopathies
Alpha 1 -antitrypsin is a member of a family of serine proteinase inhibitors termed the serpins. We and others reported the same process of polymerisation in different members of the family in association with a range of diseases: polymerisation of mutants of C1-inhibitor are associated with plasma deficiency and angio-oedema; polymerisation of mutants of antithrombin cause plasma deficiency in association with thrombosis and the polymerisation of mutants of α 1 -antichymotrypsin cause plasma deficiency that in some studies is associated with emphysema. A mutation in heparin co-factor II (Glu428Lys) that is homologous to the Z allele of α 1 -antitrypsin is associated with plasma deficiency but as yet this has not been shown to cause disease [1, 46] .
The process of disease-related polymerisation is most striking for mutations in the neurone-specific serpin neuroserpin. We showed that mutations in neuroserpin result in the formation of polymers that are retained as neuronal inclusions in the cerebral cortex [47] . These inclusions result in an autosomal dominant dementia that we called familial encephalopathy with neuroserpin inclusion bodies or FENIB [47, 48] . Six mutations have now been described that underlie FENIB [48] [49] [50] . We have assessed a range of mutants of different severity in purified recombinant protein, cell, fly, worm and mouse models of disease [48, [51] [52] [53] [54] [55] [56] [57] . The data show a direct relationship between the severity of the mutation, the rate of polymer formation and the severity of the associated dementia. In view of the common molecular mechanism underlying these disorders we grouped them together as a new class of disease-the serpinopathies [1] . The serpinopathies can cause disease by (i) a toxic gain of function from the accumulated protein, as in α 1 -antitrypsin deficiency [2] and the dementia FENIB [47] and (ii) from the lack of an important circulating inhibitor as occurs in deficiency of α 1 -antitrypsin (emphysema), antithrombin (thrombosis), C1-inhibitor (angio-oedema) and α 1antichymotrypsin (emphysema) [58, 59] . Moreover what is learned from α 1antitrypsin and neuroserpin is likely to be applicable to an entire family of disease.
Towards an effective therapy for α 1 -antitrypsin deficiency.
Behavioural approaches
The most effective current therapies for α 1 -antitrypsin deficiency are preventive. It is essential that individuals with severe α 1 -antitrypsin deficiency abstain from smoking, and ideally avoid passive exposures including dusty occupations [60] . This will help to preserve lung function. We also strongly advise against excessive consumption of alcohol §and avoiding excessive weight gain. Both alcohol consumption and high body-mass index (via fatty liver) can cause liver damage in addition to that caused by α 1 -antitrypsin deficiency.
Treatment for lung disease associated with α 1 -antitrypsin deficiency
The mainstay of treatment for severe α 1 -antitrypsin deficiency in many countries is the correction of the plasma deficiency with intravenous augmentation of pooled plasma purified α 1 -antitrypsin [61] . Augmentation therapy is associated with a reduction in the frequency of respiratory tract infections and a decline in sputum markers of inflammation. Two randomised clinical trials have been undertaken but neither has shown that augmentation therapy reduces the rate of decline in lung function [62, 63] . We have postulated that this is because the lung disease associated with α 1 -antitrypsin deficiency is caused by more than the deficiency of an important antiprotease;
the pro-inflammatory intrapulmonary polymers may negate the antiprotease effect of intravenous replacement therapy [44, 64] . Moreover, the relevance of decline in forced expiratory volume in 1 s (FEV 1 ) as an endpoint in respiratory disease is increasingly debated given recent data highlighting a developmental cause for reduced lung function [65] . The RAPID investigators have recently reported a 24 month study in which 93 individuals were randomised to active therapy and 87 to received placebo [66] . Augmentation therapy is not given with the intention of affecting the liver disease associated with α 1 -antitrypsin deficiency which appears to be predominantly driven by misfolding and polymerisation rather than loss-offunction. Theoretically there may be benefit if the excessive synthesis, misfolding and polymerisation of Z α 1 -antitrypsin is driven by an, as yet undefined, negative feedback loop driven by low levels of extracellular protein.
Moreover, anti-apoptotic and anti-inflammatory effects of extracellular α 1antitrypsin have been invoked to explain beneficial effects of α 1 -antitrypsin in a mouse model of acute liver failure [67] . Nevertheless, to date no data have indicated any signal of benefit with this treatment in liver disease.
(ii) Alternative approaches to deliver α 1 -antitrypsin replacement therapy
There are several alternative approaches to restore circulating levels of α 1antitrypsin and so protect individuals against the development of emphysema.
These include the production of recombinant α 1 -antitrypsin for replacement therapy and the delivery of α 1 -antitrypsin by an inhaled route that should significantly reduce the amount that is required to counter the effect of neutrophil elastase. A third approach is gene-based therapy using non-viral gene transfer, gamma-retrovirus, recombinant adenovirus (rAd), and recombinant adeno-associated virus (rAAV) vectors. One rAAV vector has been assessed in a phase II clinical trial, showing promise but only achieving 3-5% of the target range of α 1 -antitrypsin [68] .
(iii) Retinoic acid
Retinoic acid abrogates elastase-induced emphysema in rats [69] and so was evaluated in man [70] . 133 and 129 individuals with severe α 1 -antitrypsin deficiency were randomised to placebo or 5 mg/day palovarotene (an oral γselective retinoid agonist) respectively for 1 year (the REPAIR study: Retinoid treatment of Emphysema in Patients on the α 1 -antitrypsin International Registry). Palovarotene was generally well tolerated but there was no significant benefit on lung density in individuals with moderate-to-severe emphysema.
(iv) Symptomatic therapy, transplantation, lung volume reduction surgery and endobronchial valves
In the absence of specific therapy, individuals with α 1 -antitrypsin deficiency lung disease should be considered for therapies used in α 1 -antitrypsin replete COPD. These include pulmonary rehabilitation, vaccination and the use of The most effective therapy for individuals with severe airflow obstruction is single lung transplantation. However given the limited availability of donor organs, lung volume reduction surgery (LVRS) must be considered in these individuals possibly as definitive therapy, but more likely as a bridge to transplantation. However the benefits derived from LVRS in individuals with α 1 -antitrypsin deficiency is inferior to that of individuals who have 'usual' COPD. Further work is necessary to determine whether there is a subgroup of individuals with α 1 -antitrypsin deficiency who derive more long-lasting improvement from this intervention [71] . 
Treatment for liver disease associated with α 1 -antitrypsin deficiency
Currently there is no disease-specific therapy for the hepatic manifestations of Different groups have assessed a range of chemical chaperones that stabilise intermediates on the Z α 1 -antitrypsin folding pathway [73] . Some were effective in cell and animal models of disease [74] but human trials have been disappointing [75] . David Perlmutter's group (Pittsburgh, USA) have taken the exciting approach of using an FDA-approved drug, carbamazepine to stimulate degradation pathways to clear intracellular polymers of α 1 -antitrypsin [76] . This is now being assessed in a clinical trial (NCT01379469).
Autophagy may also be enhanced by rapamycin (sirolimus) when given in weekly dose pulses, rather than as a daily regimen. Weekly dosing of rapamycin increased the number of autophagic vacuoles and reduced the accumulation of intrahepatic polymerised Z α 1 -antitrypsin. It also reduced other markers of hepatocellular injury including cleavage of caspase 12 and hepatic fibrosis [77] . Caspase 12 is one of the inflammatory caspases that has homology to caspases 4 and 5 in humans. It plays a role in ER stress induced apoptosis in the mouse but not in man [78] . Autophagy can be induced by viral vectors that overexpress the autophagy regulator transcription factor EB (TFEB). This reduced the accumulation of Z α 1antitrypsin polymer, apoptosis and fibrosis in the liver of the transgenic mouse that expresses Z α 1 -antitrypsin [79] . These approaches reduce intracellular α 1 -antitrypsin burden and decrease hepatic fibrosis in a mouse model of disease. The challenge will be to demonstrate efficacy in man.
(ii) Modifying proteostasis networks.
An alternative approach is to consider chaperone-mediated folding and degradation as part of a robust and cooperative proteostatic network.
Suberoylanilide hydroxamic acid (SAHA) increases the secretion of Z α 1antitrypsin from epithelial cell lines to a level of 50% of that observed for wildtype α 1 -antitrypsin [80] . It is believed to act in part by inhibition of histone deacetylase (HDAC)7. Such strategies also have the potential to boost secretion of less polymerogenic α 1 -antitrypsin variants to ameliorate lung pathology e.g. in SZ compound heterozygotes. However this approach has yet to be assessed in animal models of disease.
(iii) Silencing expression of Z α 1 -antitrypsin.
Two pharmaceutical companies (Arrowhead Research Corporation and
Alnylam Pharmaceuticals Inc.) have developed RNA interference (RNAi)based approaches to silence Z α 1 -antitrypsin production in hepatocytes [81, 82] . These use small interfering (si)RNA constructs targeted against mRNA encoding human α 1 -antitrypsin and conjugated with hepatocyte targeting motifs. Treatment reduces circulating levels of α 1 -antitrypsin and both soluble and aggregated hepatic α 1 -antitrypsin protein in transgenic mice expressing Z α 1 -antitrypsin [83] . Moreover administration of the siRNA constructs arrests the progression of liver disease in these animals after short-term treatment, reverses liver disease after long-term treatment, decreases liver fibrosis and prevents liver disease in young animals. It also leads to marked reduction in liver fibrosis. The administration of RNAi treatment to non-human primates led to an approximately 80% reduction in levels of circulating normal α 1antitrypsin, demonstrating potential for this approach in man. RNAi thus represents a promising therapy for α 1 -antitrypsin deficiency related liver disease and is now in a phase I/II clinical trial (NCT02503683). The study started in July 2016 and aims to assess safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered antisense α 1antitrypsin in healthy adult subjects and individuals with Z α 1 -antitrypsin deficiency liver disease.
(iv) Small molecule approach to block intracellular polymerisation.
We have used our understanding that Z α 1 -antitrypsin polymerisation underlies the liver accumulation and subsequent plasma deficiency to develop novel strategies to attenuate polymerisation and thereby 'cure' α 1 -antitrypsin deficiency. Our early work showed that reactive loop peptides could bind to α 1 -antitrypsin and block polymerisation of purified protein in vitro [2, 84, 85] .
Smaller, refined peptides were developed that had a similar effect with more specificity for Z, rather than M, α 1 -antitrypsin [16, [86] [87] [88] . However the challenge is to deliver these peptides to cells, let alone to a human liver. A more recent approach has been to use our understanding of the structural biology of polymers to develop small molecules to block polymerisation. The starting point was the identification of a hydrophobic pocket in α 1 -antitrypsin that is bounded by strand 2A and helices D and E [89] ; Fig. 4 . The cavity is patent in the native protein but is filled as β-sheet A accepts an exogenous reactive loop peptide during polymerisation. The introduction of Thr114Phe on strand 2 of β-sheet A filled this cavity, retarded polymer formation in vitro and increased the secretion of Z α 1 -antitrypsin from a Xenopus oocyte expression system [46, 90] . This cavity was used as a target for rational structure-based drug design to block polymer formation [91] . Virtual ligand screening was performed on 1.2 million small molecules and 66 compounds were identified as potential binders. Compounds were identified that completely blocked polymerisation in vitro and in cell models of diseas [91] . 
(v) Intrabodies to block intracellular polymerisation and increase secretion
More recently we have used monoclonal antibody technology to identify interactors with Z α 1 -antitrypsin. This has proved to be powerful technology that has allowed us to identify antibodies that specifically detect the polymeric [7] and latent [92] conformers of α 1 -antitrypsin and antibodies that can accelerate [93] and block [94] polymer formation. The 4B12 monoclonal antibody blocked α 1 -antitrypsin polymerisation in vitro at a 1:1 molar ratio, causing a small increase of the stoichiometry of inhibition of neutrophil elastase [94] . Expression of a single chain-variable-fragment (scFv) intrabody of mAb4B12 within the ER reduced the intracellular polymerisation of Z α 1antitrypsin by 60% and increased the secretion of Z α 1 -antitrypsin that retained inhibitory activity against neutrophil elastase. The 4B12 monoclonal antibody recognises a discontinuous epitope in E32/H43/L306 α 1 -antitrypsin, and acts by altering protein dynamics rather than binding preferentially to the native state, analogous to the Z mutation. This novel approach could reveal new target sites for small-molecule intervention that block the transition to aberrant polymers without compromising the inhibitory activity of Z α 1antitrypsin [94] . protein misfolding, the formation of pathological polymers and the retention of polymers in the ER [95, 96] . These cells provide an invaluable resource for modelling α 1 -antitrypsin deficiency and genetic diseases. We extended this work to correct the genetic defect responsible for Z α 1 -antitrypsin deficiency within the hIPSC. This was targeted using a combination of engineered Zinc finger nucleases and a piggyBac donor vector [97] . This efficient gene editing technique restored normal structure, function and secretion of α 1 -antitrypsin in subsequently derived liver cells. These cells secreted both albumin and α 1antitrypsin when introduced into a mouse model of liver injury. The challenge is to refine the strategy, most likely with CRISPR technology, to obtain cells that are more like the fully-differentiated hepatocyte and which are safe to use in man. Nevertheless such an approach may address both the liver and lung disease associated with α 1 -antitrypsin deficiency.
A Clinical Service Perspective
We believe that patients with α 1 -antitrypsin deficiency are best cared for in collaboration with centres that offer joint respiratory-hepatology expertise.
Such services need access to appropriate diagnostics (including sequencing for the SERPINA1 gene that encodes α 1 -antitrypsin) and clinical genetics. We have therefore established these within the London Alpha-1 Antitrypsin Deficiency Service. Here we monitor the lung manifestations with regular spirometry, lung volumes and gas transfer supplemented by CT scan where this would alter management. We monitor the liver manifestations using liver biochemistry and AFP, transient elastography and liver ultrasound. We have a low threshold of liver biopsy when the above tests are abnormal. The management of lung disease in the UK is as for α 1 -antitrypsin replete COPD.
From a liver perspective, patients with α 1 -antitrypsin deficiency are advised to maintain a normal body composition and not drink alcohol to excess. As outlined here, further research is likely to lead to clear-cut benefits for the clinical management of α 1 -antitrypsin deficiency in the relatively near future.
Translational research capacity is therefore integrated into the service, including the opportunity for patients to participate in new therapeutic trials as they arise. 
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